Page 10 - Bharat Biotech

Covishield shows better antibody response than Covaxin, says study

The study was aimed at analysing the antibody response after two complete doses of Covishield and Covaxin in Indians

Do not politicise GST Council: Finance Minister Nirmala Sitharaman

The government is conscious of the intensity of the second wave of Covid-19 and is assessing its full impact before coming out with further packages and interventions, says FM Sitharaman

Bharat Biotech, Ocugen extend agreement to market Covaxin in Canada

Phase 3 analysis data to be submitted to WHO soon for EUL

Decoded: Who can get antibody cocktail for Covid-19 and how it works

Used to treat only mild to moderate disease in high-risk Covid-19 patients, doctors feel the treatment can bolster the fight against severe disease

Bharat Biotech to ramp up production of Covaxin to 100-120 mn doses by July

There has been shortage of vaccines after it was decided to open up vaccination to all those above 18 years.

World should learn the right lessons from India's Covid-19 cataclysm

All nations should now understand that vaccines work and that interfering with their supply is dangerous.

Production of Covaxin is a complex, time-consuming process: Bharat Biotech

Bharat Biotech on Friday said production and supply of Covaxin is a time-consuming process as various procedures and approvals need to be in place before it is made available for vaccination.

Shortage of transparency

Govt, companies must end opacity on vaccine supplies

Bharat Biotech gives request to Brazilian regulator for Covaxin approval

Earlier, Anvisa denied permission to import Covaxin after its authorities found that the plant in which the jab is being made did not meet the Good Manufacturing Practice (GMP) requirements

ICMR to examine effectiveness of SII's Covishield, Bharat Biotech's Covaxin

The Indian Council of Medical Research (ICMR) will conduct a survey from next week to examine the effectiveness of these vaccines in preventing progression of COVID into a severe form.

India a dysfunctional anarchy?

It is the people who lost as the government scored self-goals

Bharat Biotech expects EUL from WHO for Covaxin by Jul-Sept period

Emergency Use Listing (EUL) is a procedure to streamline the process by which new or unlicensed products can be used during public health emergencies, according to WHO guidelines

WHO nod for Covaxin expected in July-September period: Bharat Biotech

Company says regulatory approvals for Covaxin are also in process in more than 60 countries, including the US, Brazil, Hungary

Delhi yet to receive more Covid-19 vaccines for 18-44 group, says Atishi

Delhi is yet to receive more vaccines for the 18-44 age group and only private hospitals are giving jabs to beneficiaries in this category for now, Aam Aadmi Party MLA Atishi said on Tuesday

Bharat Biotech's US partner Ocugen submits 'Master File' to FDA on Covaxin

Ocugen, Bharat Biotech's American partner for Covaxin, has submitted a 'Master File' to the US Food and Drug Administration prior to seeking an emergency use authorisation in that country

WHO seeks more details from Bharat Bio for emergency use listing of Covaxin

The World Health Organisation (WHO) said more information is required from Bharat Biotech, which is seeking emergency use listing (EUL) for its Covaxin vaccine for COVID-19. The latest Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process' guidance document dated May 18 on the WHO website said Bharat Biotech submitted EOI (Expression of Interest) on April 19 and that More information required. A pre-submission meeting is expected to be planned May-June 2021, the guidance document said. According to the WHO, submissions to it for prequalification or listing under the emergency use procedure are confidential. If a product submitted for assessment is found to meet the criteria for listing, WHO will publish the results widely. Duration of the emergency use listing process depends on the quality of the data submitted by the vaccine manufacturer and on those data meeting WHO criteria, according to the agency. Meanwhile, Bharat Biotech International Limited (BBIL) has conveyed

WHO seeks more info from Bharat Biotech for emergency listing of Covaxin

The documents showed Bharat Biotech submitted Expression of Interest with the WHO for emergency use listing (EUL) on April 19

Bharat Biotech may begin Covaxin trial for 2-18 age group in June

Bharat Biotech may begin paediatric trials of its Covid-19 vaccine Covaxin from June, said the company's Business Development and International Advocacy Head Dr Raches Ella on Sunday.

No consensus yet on Covid vaccine passport issue at WHO level: Govt

'As of now, as per WHO guidelines and guidelines by other countries, people with negative COVID test report are being allowed,' says Health Ministry Joint Secretary

Bharat Biotech may receive Covaxin drug substance from IIL in June

The Union health ministry said recently that it expects 750 million doses of Covishield to be available between August and December.